Literature DB >> 2832438

Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.

V G Garzo1, J Liu, A Ulmann, E Baulieu, S S Yen.   

Abstract

The impact of the antiprogesterone RU486 [17 beta-hydroxy-11 beta-(4-dimethylaminophenyl) 17 alpha-(1-propynyl)estra- 4,9-dien-3-one] on the hypothalamic-pituitary-ovarian-endometrial axis was examined in normal cycling women during the mid (MLP)- and late (LLP) luteal phases. During the MLP, 10 women received 3 mg/kg RU486 for 3 days. During the LLP, a single dose of 600 mg RU486 was administered to 4 women, and in another 4 women a single dose of 3 mg/kg was given during corpus luteum rescue by hCG. Longitudinal studies with daily and frequent blood samples (every 10 min for 10 h) were conducted during 3 consecutive cycles (control-treatment-recovery). During the MLP, RU486-induced uterine bleeding occurred in all 10 women 36-72 h after the first dose. No histological evidence of endometrial breakdown was found in endometrial biopsies taken 12-24 h before the onset of bleeding. Significant decreases in LH secretion (P less than 0.001) and LH pulse amplitude (P less than 0.006) and blunted pituitary responses to GnRH (P less than 0.01) were evident by the last treatment day, but LH pulse frequency did not change. Complete luteolysis occurred in 2 of the 10 women. Incomplete luteolysis occurred in 8 women and was associated with an initial decline of serum estradiol (P less than 0.001), but not progesterone levels, followed by rebound increases (P less than 0.001) in LH, estradiol, and progesterone levels 3 days later, which may have reversed the luteolytic processes and prolonged corpus luteum function. Spontaneous luteolysis ensued 3-5 days later with the onset of second episodes of uterine bleeding. For serum FSH, an early rise occurred during the luteal phase in advance of the onset of the second episodes of uterine bleeding. This rise may have resulted in early follicle recruitment and accounted for the shorter duration of the follicular phase during recovery cycles. During the LLP, the single RU486 dose resulted in significant decreases in LH pulse amplitude (P less than 0.03), frequency (P less than 0.05), and secretion (not significant) within 12 h. The recovery cycle was entirely normal. Corpus luteum rescue with incremental doses of hCG did not prevent uterine bleeding after RU486 treatment. These findings indicate that RU486 operates at multiple sites and implies that progesterone is important in the control of luteal function. Further, our data provide a basis for exploring the potential use of RU486 as a once a month birth control agent.

Entities:  

Keywords:  Biology; Central Nervous System; Corpus Luteum Hormones; Data Collection; Endocrine System; Estradiol--analysis; Estrogens; Examinations And Diagnoses; Family Planning; Follicle Stimulating Hormone--analysis; Gonadotropins; Gonadotropins, Chorionic--administraction and dosage; Gonadotropins, Pituitary; Hormone Receptors--analysis; Hormones--administraction and dosage; Hormones--side effects; Hypothalamus--analysis; Laboratory Examinations And Diagnoses; Longitudinal Studies; Luteinizing Hormone--analysis; Membrane Proteins; Menstrual Cycle; Menstruation; Physiology; Progestational Hormones; Progesterone--analysis; Proteins; Reproduction; Reproductive Control Agents; Research Methodology; Studies

Mesh:

Substances:

Year:  1988        PMID: 2832438     DOI: 10.1210/jcem-66-3-508

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Medical termination of pregnancy.

Authors:  J Guillebaud
Journal:  BMJ       Date:  1990 Aug 18-25

Review 2.  Mifepristone for uterine fibroids.

Authors:  Mario Tristan; Leonardo J Orozco; Antonia Steed; Anggie Ramírez-Morera; Peter Stone
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

Review 3.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

4.  Estradiol and progesterone-induced slowing of gonadotropin-releasing hormone pulse frequency is not reversed by subsequent administration of mifepristone.

Authors:  Christopher R McCartney; Susan K Blank; John C Marshall
Journal:  Endocrine       Date:  2009-07-16       Impact factor: 3.633

5.  Mifepristone Treatment in Pregnant Murine Model Induced Mammary Gland Dysplasia and Postpartum Hypogalactia.

Authors:  Hongmei Zhu; Xuchen Jia; Mingli Ren; Liguo Yang; Jianguo Chen; Li Han; Yi Ding; Mingxing Ding
Journal:  Front Cell Dev Biol       Date:  2020-02-21

6.  Treatment of a Woman with Inoperable Meningioma Using Mifepristone for 26 Years.

Authors:  Maria das Dores Medina-Lopes; Luiz Augusto Casulari
Journal:  Case Rep Neurol Med       Date:  2020-02-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.